Serum and plasma vascular endothelial growth factor levels in testicular cancer patients [3]

Annals of Oncology

Volumn 15, Issue 6, 2004, Pages 989-990

  Ferrero, Simone ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANTICOAGULANT AGENT; CALCIUM ION; EDETIC ACID; FIBROBLAST GROWTH FACTOR; PLEIOTROPHIN; VASCULOTROPIN;

BLOOD CLOTTING; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CENTRIFUGATION; CONCENTRATION (PARAMETERS); HUMAN; LETTER; MALE; MATERIAL COATING; METHODOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; ROOM TEMPERATURE; TESTIS CANCER; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 3442899113     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh228     Document Type: Letter

References (5)

1. Aigner A, Brachmann P, Beyer J et al. Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol 2003; 14: 1525-1529.
2. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998; 94: 395-404.
3. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-1777.
4. Hormbrey E, Gillespie P, Turner K et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002; 19: 651-663.
5. Wynendaele W, Derua R, Hoylaerts MF et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 1999; 10: 965-971.